Literature DB >> 22131542

Distal myopathy with upper limb predominance caused by filamin C haploinsufficiency.

V Guergueltcheva1, K Peeters, J Baets, C Ceuterick-de Groote, J J Martin, A Suls, E De Vriendt, V Mihaylova, T Chamova, L Almeida-Souza, E Ydens, C Tzekov, G Hadjidekov, M Gospodinova, K Storm, E Reyniers, S Bichev, P F M van der Ven, D O Fürst, V Mitev, H Lochmüller, V Timmerman, I Tournev, P De Jonghe, A Jordanova.   

Abstract

OBJECTIVE: In this study, we investigated the detailed clinical findings and underlying genetic defect in 3 presumably related Bulgarian families displaying dominantly transmitted adult onset distal myopathy with upper limb predominance.
METHODS: We performed neurologic, electrophysiologic, radiologic, and histopathologic analyses of 13 patients and 13 at-risk but asymptomatic individuals from 3 generations. Genome-wide parametric linkage analysis was followed by bidirectional sequencing of the filamin C (FLNC) gene. We characterized the identified nonsense mutation at cDNA and protein level.
RESULTS: Based on clinical findings, no known myopathy subtype was implicated in our distal myopathy patients. Light microscopic analysis of affected muscle tissue showed no specific hallmarks; however, the electron microscopy revealed changes compatible with myofibrillar myopathy. Linkage studies delineated a 9.76 Mb region on chromosome 7q22.1-q35 containing filamin C (FLNC), a gene previously associated with myofibrillar myopathy. Mutation analysis revealed a novel c.5160delC frameshift deletion in all patients of the 3 families. The mutation results in a premature stop codon (p.Phe1720LeufsX63) that triggers nonsense-mediated mRNA decay. FLNC transcript levels were reduced in muscle and lymphoblast cells from affected subjects and partial loss of FLNC in muscle tissue was confirmed by protein analysis.
CONCLUSIONS: The FLNC mutation that we identified is distinct in terms of the associated phenotype, muscle morphology, and underlying molecular mechanism, thus extending the currently recognized clinical and genetic spectrum of filaminopathies. We conclude that filamin C is a dosage-sensitive gene and that FLNC haploinsufficiency can cause a specific type of myopathy in humans.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22131542     DOI: 10.1212/WNL.0b013e31823dc51e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  Novel FLNC mutation in a patient with myofibrillar myopathy in combination with late-onset cerebellar ataxia.

Authors:  Giorgio Tasca; Zagaa Odgerel; Mauro Monforte; Stefania Aurino; Nigel F Clarke; Leigh B Waddell; Bjarne Udd; Enzo Ricci; Lev G Goldfarb
Journal:  Muscle Nerve       Date:  2012-08       Impact factor: 3.217

2.  ACTA1-myopathy with prominent finger flexor weakness and rimmed vacuoles.

Authors:  Teerin Liewluck; Zhiyv Niu; Steven A Moore; Mohammad Alsharabati; Margherita Milone
Journal:  Neuromuscul Disord       Date:  2019-03-02       Impact factor: 4.296

3.  Congenital dilated cardiomyopathy caused by biallelic mutations in Filamin C.

Authors:  Eyal Reinstein; Ana Gutierrez-Fernandez; Shay Tzur; Concetta Bormans; Shai Marcu; Einav Tayeb-Fligelman; Chana Vinkler; Annick Raas-Rothschild; Dana Irge; Meytal Landau; Mordechai Shohat; Xose S Puente; Doron M Behar; Carlos Lopez-Otın
Journal:  Eur J Hum Genet       Date:  2016-09-07       Impact factor: 4.246

4.  Cyclic AMP-Rap1A signaling mediates cell surface translocation of microvascular smooth muscle α2C-adrenoceptors through the actin-binding protein filamin-2.

Authors:  Hanaa K B Motawea; Selvi C Jeyaraj; Ali H Eid; Srabani Mitra; Nicholas T Unger; Amany A E Ahmed; Nicholas A Flavahan; Maqsood A Chotani
Journal:  Am J Physiol Cell Physiol       Date:  2013-07-17       Impact factor: 4.249

5.  Filamin C-related myopathies: pathology and mechanisms.

Authors:  Dieter O Fürst; Lev G Goldfarb; Rudolf A Kley; Matthias Vorgerd; Montse Olivé; Peter F M van der Ven
Journal:  Acta Neuropathol       Date:  2012-10-30       Impact factor: 17.088

6.  Pathophysiology of protein aggregation and extended phenotyping in filaminopathy.

Authors:  Rudolf A Kley; Piraye Serdaroglu-Oflazer; Yvonne Leber; Zagaa Odgerel; Peter F M van der Ven; Montse Olivé; Isidro Ferrer; Adekunle Onipe; Mariya Mihaylov; Juan M Bilbao; Hee S Lee; Jörg Höhfeld; Kristina Djinović-Carugo; Kester Kong; Martin Tegenthoff; Sören A Peters; Werner Stenzel; Matthias Vorgerd; Lev G Goldfarb; Dieter O Fürst
Journal:  Brain       Date:  2012-09       Impact factor: 13.501

Review 7.  Emerging concepts in arrhythmogenic dilated cardiomyopathy.

Authors:  Thomas Zegkos; Theofilos Panagiotidis; Despoina Parcharidou; Georgios Efthimiadis
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

8.  Novel mutations widen the phenotypic spectrum of slow skeletal/β-cardiac myosin (MYH7) distal myopathy.

Authors:  Phillipa J Lamont; William Wallefeld; David Hilton-Jones; Bjarne Udd; Zohar Argov; Alexandru C Barboi; Carsten Bonneman; Kym M Boycott; Kate Bushby; Anne M Connolly; Nicholas Davies; Alan H Beggs; Gerald F Cox; Jahannaz Dastgir; Elizabeth T DeChene; Rebecca Gooding; Heinz Jungbluth; Nuria Muelas; Johanna Palmio; Sini Penttilä; Eric Schmedding; Tiina Suominen; Volker Straub; Christopher Staples; Peter Y K Van den Bergh; Juan J Vilchez; Kathryn R Wagner; Patricia G Wheeler; Elizabeth Wraige; Nigel G Laing
Journal:  Hum Mutat       Date:  2014-05-21       Impact factor: 4.878

9.  FLNC-Associated Myofibrillar Myopathy: New Clinical, Functional, and Proteomic Data.

Authors:  Rudolf Andre Kley; Yvonne Leber; Bertold Schrank; Heidi Zhuge; Zacharias Orfanos; Julius Kostan; Adekunle Onipe; Dominik Sellung; Anne Katrin Güttsches; Britta Eggers; Frank Jacobsen; Wolfram Kress; Katrin Marcus; Kristina Djinovic-Carugo; Peter F M van der Ven; Dieter O Fürst; Matthias Vorgerd
Journal:  Neurol Genet       Date:  2021-05-18

10.  Filamin and phospholipase C-ε are required for calcium signaling in the Caenorhabditis elegans spermatheca.

Authors:  Ismar Kovacevic; Jose M Orozco; Erin J Cram
Journal:  PLoS Genet       Date:  2013-05-09       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.